[ad_1]
The Barbara Ann Karmanos Cancer Institute has introduced a groundbreaking FDA-approved treatment for advanced liver cancer using the TheraBionic P1 device. As the first institution globally to offer this technology, Karmanos is advancing options for patients with hepatocellular carcinoma who have exhausted conventional therapies. This portable, handheld device delivers low-frequency electromagnetic fields through a simple antenna placed on the patient’s tongue during daily one-hour sessions. The treatment is designed to inhibit tumor growth while sparing healthy cells.
Studies of this advanced liver cancer treatment have demonstrated that the TheraBionic P1 can extend survival and improve the quality of life for patients facing otherwise limited options. Patient testimonials highlight the potential for prolonged life expectancy and reduced treatment-related discomfort compared to traditional methods.
Overall, the TheraBionic P1 represents a significant step in personalized and accessible cancer care.
Image Credit: The Barbara Ann Karmanos Cancer
[ad_2]
Source link
